Immunotherapy after lung cancer surgery shows promise in delaying return

This study tested whether the immunotherapy drug pembrolizumab (Keytruda) could help keep early-stage non-small cell lung cancer from returning after surgery. About 1,177 people with stage IB to IIIA lung cancer who had their tumor removed received either pembrolizumab or a placebo. The goal was to see if the drug could extend the time before the cancer came back or caused death. Results focused on patients whose tumors had high levels of a protein called PD-L1.